Pfizer Inc. (NYSE:PFE) Shares Bought by SlateStone Wealth LLC

SlateStone Wealth LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 5.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,497 shares of the biopharmaceutical company’s stock after buying an additional 508 shares during the period. SlateStone Wealth LLC’s holdings in Pfizer were worth $252,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter worth $28,000. Gladius Capital Management LP raised its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer in the fourth quarter worth $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on PFE. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.5 %

Shares of NYSE PFE opened at $25.74 on Monday. The company’s 50-day simple moving average is $26.24 and its 200-day simple moving average is $27.12. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market cap of $145.85 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.